-
Creative Medical Technology Holdings, Inc (CELZ) files for 2.79M share offering by selling stockholders
-
Creative Medical Technology Holdings secures $4.2M from warrant exercises
-
Creative Medical Technology shares shareholder letter on clinical progress
-
Creative Medical Technology receives patent allowance for heart failure treatment
-
Creative Medical Technology Holdings, Inc (CELZ) Secures FDA Clearance for Expanded Dose Escalation in the Clinical Trial of CELZ-201-DDT for Chronic Lower Back Pain
-
Creative Medical Technology (CELZ) exercises warrants for $3.7M in proceeds
-
Creative Medical Technology (CELZ) Reports Positive One-Year Results for AlloStem Type 2 Diabetes Program
-
Creative Medical Technology (CELZ) Expands Collaboration with Greenstone Biosciences to Accelerate iPSCelz Pipeline Development
-
Creative Medical Technology Holdings, Inc (CELZ) Announces Positive Initial Safety, Tolerability, and Efficacy Data from First Cohort in Phase 1/2 Trial of CELZ-201-DDT
-
Creative Medical Technology (CELZ) Advances FDA Cleared ADAPT Clinical Trial with Positive Independent Review, Validating the Safety and Potential of CELZ-201 for Chronic Lower Back Pain Treatment
-
Creative Medical Technology (CELZ) Files $50M Mixed Shelf
-
Creative Medical Technology (CELZ) Initiates Development of AI-Driven Diagnostic and Treatment Program for Biologic and Chemical Exposure
-
Creative Medical Technology Holdings (CELZ) Issues Corporate Update
-
Roth/MKM Reiterates Buy Rating on Creative Medical Tech Holdings Inc. (CELZ)

